Will migraine drug approval make Teva a success again?
The U.S. Food and Drug Administration approved a new migraine treatment Teva created, which has potentially 39 million Americans buyers.
By REUTERS, TNSAn Israeli flag flutters near the logo of Teva Tech which is part of Teva Pharmaceutical Industries in Neot Hovav, southern Israel December 14, 2017.(photo credit: REUTERS/AMIR COHEN)
Israeli drugmaker Teva Pharmaceutical Industries on Friday received approval from the US Food and Drug Administration (FDA) to sell its new migraine treatment, a key drug the company has been banking on to help revive its fortunes.The world's largest generic drugmaker had hoped to receive approval for the injectable drug, fremanezumab, by June. Its release was delayed due to US regulatory concerns about the manufacturing process at the South Korean plant of its development partner Celltrion.Around 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, making for a large market that has attracted several drugmakers.In August the FDA granted marketing approval for a first generic Teva produced version of EpiPen, Mylan's branded treatment for severe, life-threatening allergies.Mylan for its part brought to market the first generic version of Teva's 40 mg dosage of flagship blockbuster drug Copaxone for the treatment of multiple sclerosis in late 2017.
Related TagsTeva
if(catID != 151){
var cont = `Take Israel home with the new Jerusalem Post Store
